PeptideIntel

CJC-1295 + Ipamorelin Stack

The most popular GH-secretagogue combination protocol — pairing a GHRH analog with a selective GHSR agonist to target two complementary GH-release pathways simultaneously.

Last updated

Components

CJC-1295

Human obs.

CJC-1295 with DAC · Drug Affinity Complex-GHRH

A long-acting GHRH analog engineered for albumin conjugation — the first GH-secretagogue peptide demonstrated to sustain elevated GH and IGF-1 for over a week in a human pharmacokinetics study.

Research compound

Ipamorelin

Animal

NNC 26-0161

A selective, pentapeptide GH secretagogue with a cleaner pituitary-selectivity profile than older GHRP compounds — but characterized almost entirely in animal models, with minimal published human data.

Research compound

Rationale (from the literature)

The rationale is pharmacologically coherent: CJC-1295 activates the GHRH receptor on pituitary somatotrophs, while ipamorelin activates the ghrelin receptor (GHSR-1a). These two receptor populations converge on the same end result — GH secretion — but through distinct intracellular signaling. Combining them is expected to produce additive or synergistic GH pulse amplification greater than either agent alone. This principle has been demonstrated in animal models. The appeal of ipamorelin specifically as the GHSR component is its selectivity: it stimulates GH without the cortisol and prolactin elevation seen with GHRP-2 or GHRP-6. CJC-1295 with DAC contributes extended duration, reducing injection frequency.

Honest caveats

  • No published human clinical trial has tested this specific combination for any outcome
  • All supporting evidence is from animal pharmacology and human PK/PD data for the individual compounds
  • The "selective" profile of ipamorelin is established in animals, not confirmed in human comparative trials
  • Both components are research compounds sold for research use only; human safety over time is unknown
  • Combining two GH-stimulating agents may increase the risk of GH-related side effects (fluid retention, insulin resistance)
  • Both are banned in sport by WADA
  • Any circulating dosing protocol is extrapolated from animal data and individual compound PK, not clinically validated